Table 2 Challenges in assessing routine TB screening, diagnosis, treatment and prevention services in countries during the COVID-19 pandemic
Variables | Overall (n = 124) | West Africa (n = 72) | Europe (n = 52) |
|---|---|---|---|
Are there general challenges with routine TB screening and diagnosis? | |||
 Yes, n (%) | 62 (50.0) | 37 (51.4) | 25 (48.1) |
 No, n (%) | 54 (43.5) | 30 (41.7) | 24 (46.1) |
Don’t know, n (%) | 8 (6.5) | 5 (6.9) | 3 (5.8) |
Are there general challenges with routine TB treatment and prevention? | |||
 Yes, n (%) | 46 (37.1) | 28 (38.9) | 18 (34.6) |
 No, n (%) | 70 (56.5) | 39 (54.2) | 31 (59.6) |
 Don’t know, n (%) | 8 (6.4) | 5 (6.9) | 3 (5.8) |
Is it more difficult for presumed TB patients to access diagnosis and care services? | |||
 Yes, n (%) | 37 (29.8) | 26 (36.1) | 11 (21.1) |
 No, n (%) | 75 (60.5) | 41 (56.9) | 34 (65.4) |
 Don’t know, n (%) | 12 (9.7) | 5 (6.9) | 7 (13.5) |
Is it more difficult for TB patients to receive their TB drug supply or to have direct observation of their treatment? | |||
 Yes, n (%) | 27 (21.8) | 18 (25.0) | 9 (17.3) |
 No, n (%) | 87 (70.2) | 49 (68.1) | 38 (73.1) |
 Don’t know, n (%) | 10 (8.0) | 5 (6.9) | 5 (9.6) |